| Characteristics | Training Cohort | Testing Cohort |
|---|---|---|
| Patients, n | 44,745 | 44,745 |
| Age, mean (SD) | 54.5 (10.2) | 54.6 (10.2) |
| Female, n (%) | 24,289 (54.3) | 24,424 (54.6) |
| Regions, n (%) | ||
| Midwest | 10,422 (23.3) | 10,471 (23.4) |
| Northeast | 3,431 (7.7) | 3,566 (8.0) |
| South | 25,054 (56.0) | 25,013 (55.9) |
| West | 5,838 (13.0) | 5,695 (12.7) |
| Use of preventive service, n (%) | ||
| Fecal blood tests | 4,166 (9.3) | 4,178 (9.3) |
| Colonoscopy | 3,984 (8.9) | 3,904 (8.7) |
| Mammography | 8,585 (19.2) | 8,540 (19.1) |
| Number of hospitalizations, mean (SD) | 0.17 (0.6) | 0.17 (0.6) |
| Days in hospital, mean (SD) | 0.88 (4.6) | 0.90 (4.5) |
| Comorbidities, n (%) | ||
| PVD | 1,529 (3.4) | 1,502 (3.4) |
| Liver disease | 1,938 (4.3) | 1,957 (4.4) |
| Renal disease | 2,399 (5.4) | 2,434 (5.4) |
| Recent MI | 588 (1.3) | 593 (1.3) |
| Prior MI | 754 (1.7) | 770 (1.7) |
| Recent stroke | 289 (0.7) | 313 (0.7) |
| Prior stroke | 391 (0.9) | 418 (0.9) |
| Ischemic heart disease | 5,191 (11.6) | 5,207 (11.6) |
| Transient ischemic attack | 158 (0.4) | 132 (0.3) |
| Hypertension | 25,051 (56.0) | 25,156 (56.2) |
| Diabetes | 11,653 (26.0) | 11,579 (25.9) |
| Depression | 6,517 (14.6) | 6,544 (14.6) |
| Cancer | 5,978 (13.4) | 5,882 (13.2) |
| Combined comorbidity score, mean (SD) | 0.16 (1.5) | 0.17 (1.5) |
| Baseline medications, n (%) | ||
| ACEI | 15,548 (34.8) | 15,480 (34.6) |
| ARB | 8,580 (19.2) | 8,576 (19.2) |
| Beta blockers | 11,182 (25.0) | 11,445 (25.6) |
| Calcium channel blockers | 9,253 (20.7) | 9,266 (20.7) |
| Thiazides | 14,850 (33.2) | 14,861 (33.2) |
| Baseline medications, n (%) | ||
| Oral anticoagulants | 1,484 (3.3) | 1,537 (3.4) |
| Antiplatelets | 1,708 (3.8) | 1,713 (3.8) |
| Antidiabetics | 11,286 (25.2) | 11,229 (25.1) |
| NSAIDs | 10,200 (22.8) | 10,105 (22.6) |
| SSRIs | 9,652 (21.6) | 9,698 (21.7) |
| Other lipid-lowering agents | 2,169 (4.9) | 2,223 (5.0) |
| Index statin, n (%) | ||
| Atorvastatin | 7,466 (16.7) | 7,601 (17.0) |
| Fluvastatin | 47 (0.1) | 57 (0.1) |
| Lovastatin | 2,208 (4.9) | 2,174 (4.9) |
| Pitavastatin | 501 (1.1) | 545 (1.2) |
| Pravastatin | 8,257 (18.5) | 8,127 (18.2) |
| Rosuvastatin | 6,440 (14.4) | 6,271 (14.0) |
| Simvastatin | 19,826 (44.3) | 19,970 (44.6) |
| High-intensity dose | 4,090 (9.1) | 3,931 (8.9) |
| Refill synchronization measure | 0.26 (0.2) | 0.26 (0.2) |
| Medication burden, mean (SD) | ||
| Number of drug dispensations | 26.4 (21.9) | 26.5 (21.9) |
| Number of unique drugs dispensed | 7.6 (5.2) | 7.6 (5.2) |
| Number of drugs dispensed with days supply overlapping index | 2.4 (2.3) | 2.4 (2.3) |
| Plan benefit type, n (%) | ||
| POS | 30,753 (68.7) | 30,747 (68.7) |
| EPO | 7,118 (15.9) | 7,028 (15.7) |
| HMO | 3,706 (8.3) | 3,733 (8.3) |
| IND | 1,753 (3.9) | 1,856 (4.2) |
| PPO | 1,357 (3.1) | 1,336 (3.0) |
| Other | 58 (0.1) | 45 (0.1) |
| Financial burden | ||
| Total deductibles in U.S. dollars, mean (SD) | 557.8 (547.6) | 559.6 (560.6) |
| Copay of index statin in U.S. dollars, mean (SD) | 17.0 (19.5) | 16.9 (19.3) |
ACEI = angiotensin-converting enzyme inhibitors, ARBs = angiotensin II receptor blockers; EPO = exclusive provider program; HMO = health maintenance organization; IND = individual health plan; MI = myocardial infarction; NSAIDs = nonsteroidal anti-inflammatory drugs; POS = point-of-service; PPO = preferred provider organization; PVD = peripheral vascular disease; SD = standard deviation; SSRIs = selective serotonin reuptake inhibitors.